Introduction
Oral squamous cell carcinoma (OSCC) is one of the most common head and neck malignancies, characterized by high mortality rate and poor prognosis.
1,2 OSCC development is a multistep process caused by accumulated genetic and epigenetic alterations; it further leads to deregulation of key cellular signaling pathways, thus contributing to tumor initiation and progression. 3, 4 Several risk factors have been identified to be involved in oral carcinogenesis, such as betel quid or areca nut chewing, tobacco smoking, alcohol consumption, and viral infections.
OSCC is preceded by some precancerous lesions, including oral leukoplakia, oral lichen planus, and oral submucous fibrosis (OSF). 2, 4 Seven to thirty percent of OSF cases develop OSCC based on epidemiology studies and are always coincident with OSCC clinically. 5, 6 Betel quid chewing is a critical risk factor for OSF. 7, 8 However, few studies have been performed to elucidate the key genes and cell signaling pathways deregulated at the early stage of OSCC. 
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Zhou et al Wnt/β-catenin signaling is one of the most crucial pathways involved in the development of multiple malignancies, including OSCC, through regulating cell proliferation, differentiation, adhesion, stemness, metastasis, and invasion. [9] [10] [11] Multiple intracellular and extracellular components concordantly regulate Wnt/β-catenin signaling pathway in tumorigenesis. 12 β-Catenin is the key mediator of canonical Wnt signaling, and its activation contributes to tumor development and progression. β-Catenin could be released from the membrane and translocated into the nucleus, which further binds to TCF/LEF-1 family of transcription factors and activates target genes, resulting in Wnt signaling pathway activation. In OSCC, aberrant expression of β-catenin was associated with poor survival and nodal metastases, as well as increased mortality risk. [13] [14] [15] [16] [17] [18] In addition, a group of secreted Wnt antagonists have been implicated in the regulation of Wnt/β-catenin-signaling pathway, including Wnt inhibitory factor 1, secreted frizzledrelated protein (SFRP), and the Dickkopf families. The SFRP family contains five glycoproteins (SFRP1, -2, -3, -4, and -5) and inhibits the Wnt signaling pathway through binding WNT ligand and competing with frizzled (Fz) receptors. 19 Reduced SFRPs (SFRP1, -2, -4, and -5) in messenger RNA (mRNA) levels has been identified in a variety of malignancies including OSCC. 20, 21 However, little is known about SFRPs and β-catenin expression and their clinical significance in the carcinogenesis of OSF.
In this study, we selected two (SFRP1 and SFRP5) of the five SFRP members as representatives to investigate expression of SFRPs and their roles in OSF and OSCC pathogenesis. We examined the expression of SFRPs and β-catenin in normal oral mucosa, OSF, and OSCC tissues, as well as the correlation with clinicopathological features. We also investigated related regulatory mechanism of SFRPs reduction in OSF progression. , and β-catenin expression, a scoring method was used. A mean percentage of positive cells were determined by the examination of 500 cells in at least five areas at ×400 magnification. Cells were assigned to one of the five following categories according to the percentage of positive cells (PP): 0) ,5%; 1) 5%-24%; 2) 25%-49%; 3) 50%-75%; and 4) .75%. The intensity of the SFRP1, SFRP5, and β-catenin staining (SI) was then scored as follows: negative, − (0); weak, + (1); moderate, ++ (2); and intense, +++ (3). 
Materials and methods

reverse-transcription polymerase chain reaction
Total RNAs were extracted using Trizol Legend (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instruction. Reverse-transcription polymerase chain reaction (RT-PCR) was performed with the use of a kit from Promega Corporation (Fitchburg, WI, USA). Real-time PCR was performed to detect SFRP1 and SFRP5 expression, according to the manufacturer's protocol (HT7500 system; Thermo Fisher Scientific). Primers for amplifying SFRP1 and SFRP5 mRNA sequences were synthesized as described previously. 23 The 497 bp mRNA of SFRP1 was amplified by PCR with forward primer 5′-CCAGCGAGTACGACTACGTGAGCTT and reverse primer 5′-CTCAGATTTCAACTCGTTGTCACAGG. The 546 bp mRNA of SFRP5 was amplified by PCR with forward primer 5′-TGCGCCCAGTGTGAGATGGAGCAC and reverse primer 5′-CCCATCCCTTAGGCCTTGTGCCAGT. GAPDH was used as an internal control, the forward primer: 5′-ATCTCTGCCCCCTCTGCTGA-3′ and the reverse primer 5′-GATGACCTTGCCCACAGCCT-3′. PCR amplification was performed with denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, and extension at 72°C for 30 seconds in 32 cycles. The PCR products were visualized on 2% agarose gels under ultraviolet transillumination.
Methylation-specific PCR
Bisulfite modification of DNA and methylation-specific PCR were performed as described previously. [24] [25] [26] [27] The bisulfite-treated DNA was amplified with the methylation-specific primer sets:
23 SFRP1-Nm3: 5′-TGTAGTTTTCGGAGTTAGTGTCGCGC, SFRP1-m2: 5′-CCTACGATCGAAAACGACGCGAACG or the unmethylation-specific primer set SFRP1-u1: 5′-GTTT TGTAGTTTTTGGAGTTAGTGTTGTGT, SFRP1-u2: 5′-CTCAACCTACAATCAAAAACAACACAAACA. SFRP5-Nm3: 5′-AGATTTGGCGTTGGGCGGGACGTTC, SFRP5-Nm4: 5′-ACTCCAACCCGAACCTCGCCGTACG or the unmethylation-specific primer set SFRP1-u1: 5′-ATTTGGTGTTGGGTGGGATGTTT, SFRP1-u2: 5′-CCAACCCAAACCTCACCATACA. Methylationspecific PCR was done using AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA) (methylation-specific primer: annealing temperature 60°C, 40 cycles and unmethylationspecific primer: annealing temperature 58°C, 40 cycles).
Results
reduced expression of sFrP1 and sFrP5 in the carcinogenesis of OsF
We first examined protein expression levels of SFRP family members (SFRP1 and SFRP5) by immunohistochemistry staining using SFRP1-and SFRP5-specific antibodies in normal oral mucous samples, OSF samples, and OSCC cases with betel quid chewing habit. SFRP1 and SFRP5 expressions were detected in all samples at variable intensities (Figures 1 and 2) . Twelve of 15 (80.0%) normal oral mucous tissues showed nuclear SFRP1 positivity, whereas 30 of the 45 (66.7%) OSF tissues showed cytoplasmic SFRP1 expression, including tissues from 12 of the 15 (80.0%) early stage, 10 of the 15 (66.7%) moderately advanced Figure 2 and Table 2 ).
The average values of SFRP1 and SFRP5 expression varied in different tissue samples, with mean score of 4.47 and 4.80 in normal oral mucous tissues, respectively, 3.09 and 3.22 in OSF tissues, as well as 2.05 and 2.00 in OSCC tissues, respectively (Tables 1 and 2 ). SFRP1 and SFRP5 expressions were gradually reduced in normal oral mucous tissues, OSF tissues, and OSCC tissues (P=0.01125, P=0.00046). These data suggest that SFRP1 and SFRP5 are downregulated in the carcinogenesis of OSF.
association of sFrP1, sFrP5, and β-catenin expressions and the correlation with clinicopathological features
To determine whether decreased SFRP1 and SFRP5 would cause Wnt/β-catenin signaling pathway activation, we further examined β-catenin expression in normal oral mucous samples, OSF samples, and OSCC cases with betel quid chewing habit. In normal oral mucous and OSF tissues, homogeneous membranous staining of β-catenin was observed, while increased cytoplasmic/nuclear (C/N) staining of β-catenin was shown in OSCC tissues, without membranous staining (Figure 3 ). However, we did not find significantly increased β-catenin expression in OSCC tissues, compared with normal oral mucous and OSF tissues (P.0.05).
We further analyzed the association of SFRP1 and SFRP5 expression with the distribution of β-catenin in OSCC cases with betel quid chewing habit. In OSCC tissues with reduced SFRP1 expression, 25 of the 31 samples (80.6%) were 
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The association among SFRP1, SFRP5, and β-catenin expressions, as well as clinicopathological characteristics was examined. No significant association was found between SFRP1 and SFRP5 expressions with any of the clinical parameters investigated (Table 4) , whereas there was a significant correlation between primary tumor and TNM stage with β-catenin expression (P=0.00798). β-Cateninpositive expression was observed in 100% (43/43) of OSCC patients with T3 + T4 and late TNM stage (III-IV) and 75.0% (9/12) of OSCC patients with T1 + T2 and early TNM stage (I-II).
sFrP1 and sFrP5 are downregulated at mrna levels in the carcinogenesis of OsF
We also examined SFRP1 and SFRP5 expressions at mRNA levels in normal oral mucous tissues, OSF tissues, OSCC, and their paired adjacent tissues by semiquantitative RT-PCR. We found that SFRP1 and SFRP5 were readily expressed in normal oral mucous tissues ( Figure 4A ) and Abbreviations: sFrP, secreted frizzled-related protein; Oscc, oral squamous cell carcinoma; Mem, membranous stain; c/n, cytoplasmic/nuclear. 
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Zhou et al OSF early stage tissues, but decreased in OSF moderately advanced stage tissues, whereas rarely expressed in OSF advanced stage tissues ( Figure 4B ). We also detected SFRP1 and SFRP5 expression in OSCC and their adjacent OSF or normal oral mucous tissues. Results showed that SFRP1 and SFRP5 were downregulated in OSCC tissues, compared with their paired adjacent OSF or normal mucous tissues ( Figure 4C and D) . Real-time RT-PCR further confirmed reduced expression of SFRP1 and SFRP5 in OSCC tissues, compared with their adjacent normal or OSF tissues ( Figure 4E ). Therefore, SFRP1 and SFRP5 mRNA expression levels are decreased in the carcinogenesis of OSF.
Promoter methylation of sFrP1 and sFrP5 in the carcinogenesis of OsF
We further investigated possible regulatory mechanism of SFRP1 and SFRP5 reduction in the carcinogenesis of OSF. As promoter methylation mediates tumor suppressor genes transcriptional repression, we next detected promoter methylation of SFRP1 and SFRP5 in normal oral mucous and OSF tissues, OSCC, and their paired adjacent OSF or normal tissues. We found that SFRP1 and SFRP5 methylation was not detected in ten normal oral tissues and ten OSF tissues from early stage, moderately advanced stage, and advanced stage ( Figure 5A and B). We also found that SFRP1 and SFRP5 were frequently methylated in OSCC tumor tissues but barely methylated in their paired adjacent OSF and normal oral mucous tissues ( Figure 5C and D). These data suggest that promoter methylation of SFRP1 and SFRP5 is tumor-specific event in the carcinogenesis of OSF.
Discussion
SFRPs are the largest family of Wnt-negative modulators and the first Wnt antagonists to be identified. SFRP proteins contain ∼300 amino acids, including a cysteine-rich domain (CRD) in N-terminal domain and a hydrophilic heparinbinding region in C-terminal domain. Its CRD domain has ten conserved cysteine residues, with high homology to the extracellular CRD domain of the Fz receptors. 19 Thus, SFRPs as secreted glycoproteins could bind directly to Wnt ligands or Fz receptors, leading to the suppression of Wnt/β-catenin signaling.
Epigenetic silencing of Wnt antagonists has been welldocumented in human malignancies. 28 Promoter methylation is the major regulatory mechanism. Deregulation of SFRPs by promoter CpG methylation has been reported in multiple human cancers, including oral, 20 nasopharyngeal, esophageal, lung, gastric, colorectal, hepatocellular, breast, ovarian, 
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Zhou et al endometrial, cervical, renal, and bladder carcinomas. 19 Methylated SFRP1, SFRP2, SFRP4, and SFRP5 could mediate tumor cell proliferation, differentiation, apoptosis, and progression. 19 Loss of SFRP1 expression in the early stage of breast cancer is associated with poor prognosis, thus is a novel prognostic early marker for breast cancer. [29] [30] [31] Therefore, deregulation of Wnt antagonists SFRPs could be an early event in the multiple-step tumorigenesis of OSCC. However, there is no report about SFRPs expression in OSCC, especially in the precancerous lesion (OSF). SFRP2, SFRP4, and SFRP5 have been found to be reduced by promoter methylation in OSCC samples, 20, 21 whereas one group reported that SFRP1 demethylated in OSCC. 21 Here, we selected SFRP1 and SFRP5, two representative members of SFRP family, to study the roles of SFRP family members in the carcinogenesis of OSCC. We first found that SFRP1 and SFRP5 were downregulated in the precancerous OSF and OSCC with varied protein levels.
Activation and delocalization of β-catenin in precancerous oral lesions and oral cancers have been found, suggesting the importance of Wnt/β-catenin signaling pathway in OSCC tumorigenesis. We thus evaluated whether reduced SFRP1 and SFRP5 would activate Wnt/β-catenin signaling pathway. We found significant association between decreased SFRP1, SFRP5, and β-catenin C/N expression in the carcinogenesis of OSF, which was correlated with poor prognosis of OSCC. Infrequent mutations of β-catenin, Adenomatous polyposis coli, and Axin1 were reported in oral cancer, 32, 33 which indicates that epigenetic silencing of Wnt signaling components plays an important role in OSCC pathogenesis. 21 We further investigated the regulatory mechanism of SFRP1 and SFRP5 downregulation in the carcinogenesis of OSF. We found that promoter methylation mediated their silencing in OSCC patient tissues with betel quid chewing habit but not in normal oral mucous tissues and their paired adjacent normal or OSF tissues, which are consistent with other reports of SFRPs methylation in OSCC from the population of Western.
Conclusion
In summary, this is the first report to show downregulation of Wnt antagonists, SFRP1 and SFRP5, at protein and mRNA levels in the carcinogenesis of OSF. Deregulation of SFRP1 and SFRP5 by promoter methylation, coupled with activated β-catenin, may result in OSF canceration and OSCC progression. Tumor-specific methylation of SFRPs in OSCC will help to develop biomarker for early detection and personalized medicine of OSCC patients.
